This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Products from multiple soldto's are in cart. Only products from single soldto is allowed in cart.
No Items In Cart
Spotting a quality issue on a stopper or plunger can be difficult. While a trimming or molding defect may be noticeable, embedded particulate or foreign contamination may be far too small for the human eye to see.
Take for example, the image of the plunger below. At actual size, which is about as big as a fingernail, would you be able to spot the defect?
Vision verification is an established and easy way of improving the quality of pharmaceutical components. Through the use of automatic, program-controlled vision inspection technology, all surfaces of a component can be quickly and easily verified – helping to increase product yield by reducing the number of rejects. Automated inspection also can help to reduce waste and increase operational efficiency by optimizing throughput.
The above image shows how the use of vision verification may help to make notable improvements in consistency and yield rates.
West is a pioneer in vision inspection technology. The Envision® automated inspection system can enhance the quality of Westar® ready-to-sterilize components by significantly reducing adhered and embedded particulate, helping to improve consistency.
Many of our standard products are available in Envision-verified formats – an upgrade that can be made simply by talking to your sales representative as there’s no need for a complex development agreement or even additional regulatory work. Your current item may already be available with Envision verification, allowing you to benefit from the advantages of a tighter specification and reduced end of line component failure risks while preserving all the features of your current formulation, configuration, finishing, packaging and other key details. This approach to upgrade, which leaves the fundamentals of your component’s production and preparation unchanged, is not associated with any additional testing or regulatory reporting work.
Contact a West Technical Customer Service representative today to see if your products are pre-qualified as Envision-verified components.
Envision® and Westar® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
Take an in-depth look at the science behind containment & delivery ofinjectable medicines in the West Knowledge Center.
Final packaging is often the last process step before a product leaves a factory. Any failure in the process at this point puts the cost of the finished and filled drug at risk, as well as the capacity of the process.<br />
<p>By William and Suzette Rishel</p><p><em>Bill and Suzette Rishel are team members at West’s Jersey Shore, Pa., facility. Bill serves as Value Stream Lead and Suzette as a Quality Assurance Inspector.</em></p>
Critical quality attributes (CQAs) of biologic drug products can be affected by multiple factors throughout the product lifecycle, including the container closure and delivery systems. Diane Paskiet, Director of Scientific Affairs at West Pharmaceutical Services, discussed containment and delivery system compatibility with biologic drug products along with regulatory considerations in her presentation Establishing Safety of Container Closure and Delivery Device Systems at the PepTalk 2017 conference. Evaluating potential impacts early, holistically, and throughout bioprocessing can facilitate decisions at each step that will minimize risks to CQAs and safety.
When the COVID-19 Pandemic shut down the ability for in-person tradeshows and events, we worked to find an alternative solution with a new virtual exhibit designed to replicate the West experience without the risk of in-person interactions. Our team members quickly turned the idea of a booth replacement into an interactive experience for customers to use – both during trade shows and any time there’s a need to connect with us.
As the adoption and acceptance of self-administered therapies grows, patients are spending less time with physicians and are playing a greater role in the delivery and management of their treatments. With the growing demand for extended-release and high-concentration formulations, more drug delivery systems choices are now available to differentiate drug products in a crowded market. Patient preferences can drive the selection of self-injection systems for a drug therapy. Selecting a system that patients prefer can, simplify use and increase compliance with the dosage regimen.